ArticleFrontiers in neuroscience2026
Screening the optimal rTSMS frequency to orchestrate immune-fibrotic remodeling for adult spinal cord repair.
Article in Frontiers in neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The clinical translation of magnetic stimulation for central nervous system trauma is severely hindered by "parameter ambiguity"-the lack of evidence-based screen of stimulation protocol. Repetitive trans-spinal magnetic stimulation (rTSMS) holds therapeutic promise, yet its frequency-dependent effects on the complex spinal microenvironment remain poorly understood. To address this gap, this study aimed to decode the frequency-response relationship of rTSMS and establish an optimal, evidence-based frequency standard to orchestrate immune-fibrotic remodeling and promote functional recovery following spinal cord injury (SCI). Methods: Utilizing novel Results: We identified 40 Hz as a privileged therapeutic frequency that specifically modulates microglia and the extracellular matrix. Unlike 10 Hz or 80 Hz regimens, 40 Hz rTSMS uniquely reprogrammed the transcriptomic landscape, driving microglia toward a restorative M2 phenotype, and most importantly, suppressing collagen fibrillogenesis. This targeted modulation effectively attenuated fibrotic scarring and preserved mitochondrial dynamics and axonal integrity. Consequently, the 40 Hz protocol significantly enhanced corticospinal tract conduction and drove robust, long term sensorimotor recovery. Conclusion: Our findings define 40 Hz as the critical therapeutic standard for coupling immune modulation with fibrotic remodeling in SCI. By overcoming the barrier of inconsistent parameters, this study provides a precise, clinically translatable framework for the application of rTSMS in neurorestorative medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.